Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Researchers evaluate Pexa-Vec to slow progression of liver cancer

Researchers evaluate Pexa-Vec to slow progression of liver cancer

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

Tivozanib overall survival results announced by AVEO and Astellas

Tivozanib overall survival results announced by AVEO and Astellas

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Targeted therapy as common as chemotherapy at end of life

Targeted therapy as common as chemotherapy at end of life

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Tumour burden predicts prognosis in mRCC

Tumour burden predicts prognosis in mRCC

Scientists show how sorafenib can be dangerous to the heart

Scientists show how sorafenib can be dangerous to the heart

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Sorafenib does not improve overall survival among patients with NSCLC

Sorafenib does not improve overall survival among patients with NSCLC

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study